Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2020-11-09 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
未来三年（2020-2022年）股东回报规划
Notice of Dividend Amount Classification · 90% confidence The document is titled as a "Future Three-Year (2020-2022) Shareholder Return Plan" issued by the company's board. It outlines the company's profit distribution policy, principles, and mechanisms for shareholder returns over a multi-year period. The content focuses on dividend policy, cash and stock dividend distribution, decision-making processes, and shareholder communication. It is not a financial report with actual financial statements or earnings data, nor is it an announcement of voting results or a regulatory filing. It is a detailed policy document related to dividend planning and shareholder returns, which fits best under the category of Notice of Dividend Amount (DIV) because it deals with dividend distribution plans and policies, even though it is a multi-year plan rather than a single dividend announcement. The document length is 2046 characters, which is relatively short but contains substantive policy content rather than just an announcement or a link to a report. Therefore, the best classification is DIV with high confidence.
2020-11-09 Chinese
独立董事关于第五届董事会第十次会议相关议案的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion statement from independent directors regarding the pre-approval of proposals related to a specific board meeting (the 10th meeting of the 5th board). The content focuses on the independent directors' opinions on the company's plan to issue shares to specific investors, including the feasibility, compliance with laws, and impact on shareholders. It does not contain financial statements or detailed financial data but rather expresses approval and recommendations for board consideration. The document is relatively short (2518 characters) and serves as a formal pre-approval or opinion letter rather than a full report or announcement of results. It is not a full Annual Report, Interim Report, or Earnings Release. It is also not a regulatory announcement or a report publication notice. The document fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on corporate actions.
2020-11-09 Chinese
第五届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 10th meeting of the 5th Board of Directors of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.) held on November 6, 2020. It includes multiple board decisions related to a proposed private placement of A shares to specific investors, including approval of the issuance plan, pricing, number of shares, use of proceeds, and authorization for the board to handle related matters. It also includes a board member resignation and nomination, and notice of a forthcoming extraordinary general meeting to approve these matters. The document contains voting results and independent directors' opinions. The content is focused on board-level decisions and management changes, not a full financial report or earnings release. It is not a shareholder meeting presentation or voting result announcement, but a board meeting resolution announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (9649 characters) and detailed content support this classification with high confidence.
2020-11-09 Chinese
向特定对象发行A股股票募集资金运用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled '向特定对象发行A股股票募集资金运用的可行性分析报告' which translates to 'Feasibility Analysis Report on the Use of Funds Raised by Private Placement of A Shares'. It discusses the company's plan to raise capital through a specific share issuance, detailing the investment projects, their necessity, feasibility, and expected financial impact. The content includes extensive analysis of the capital raising plan, investment projects, and their strategic importance. This aligns with the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive content about the capital raising and use of proceeds, not merely an announcement or a brief summary. Therefore, the appropriate classification is CAP with high confidence.
2020-11-09 Chinese
关于2020年度创业板向特定对象发行股票摊薄即期回报、填补即期回报措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 康芝药业股份有限公司 regarding a specific issuance of shares to particular investors in 2020. It discusses the dilution of immediate returns due to this issuance, the impact on key financial indicators, risk warnings, the necessity and rationality of the issuance, and commitments by the company's board and controlling shareholders to mitigate dilution effects. The document references regulatory guidelines and includes detailed financial impact calculations and management commitments. It is not a full annual or interim report but a detailed announcement about a capital raising event and its financial implications. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (7577 characters) and content confirm it is a substantive announcement rather than a brief notice or a report publication announcement.
2020-11-09 Chinese
关于无需出具前次募集资金使用情况报告的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 康芝药业股份有限公司 stating that the company does not need to produce a report on the use of previously raised funds because the last fundraising was more than five accounting years ago. It references regulatory requirements from the China Securities Regulatory Commission about fundraising reports but does not contain any financial statements or detailed financial data. The document is short (689 characters) and serves as a formal announcement regarding compliance with fundraising reporting rules, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2020-11-09 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.